Cns Pharmaceuticals Inc (NASDAQ: CNSP) has experienced a decline in its stock price by -13.87 compared to its previous closing price of 3.75. However, the company has seen a fall of -40.07% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-20 that Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?
Cns Pharmaceuticals Inc (NASDAQ: CNSP) has a price-to-earnings ratio of 0.00x that is above its average ratio. Additionally, the 36-month beta value for CNSP is 1.06. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CNSP is 2.73M and currently, short sellers hold a 0.05% ratio of that float. The average trading volume of CNSP on February 24, 2025 was 549.93K shares.
CNSP’s Market Performance
CNSP stock saw a decrease of -40.07% in the past week, with a monthly decline of -37.28% and a quarterly a decrease of -46.17%. The volatility ratio for the week is 33.41%, and the volatility levels for the last 30 days are 17.71% for Cns Pharmaceuticals Inc (CNSP). The simple moving average for the past 20 days is -35.74% for CNSP’s stock, with a -95.81% simple moving average for the past 200 days.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -39.27% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.73% of loss for the given period.
Volatility was left at 17.71%, however, over the last 30 days, the volatility rate increased by 33.41%, as shares sank -32.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.67% lower at present.
During the last 5 trading sessions, CNSP fell by -40.07%, which changed the moving average for the period of 200-days by -99.42% in comparison to the 20-day moving average, which settled at $5.03. In addition, Cns Pharmaceuticals Inc saw -46.35% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -2684.89 for the present operating margin
- 0.6 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -2681.03. The total capital return value is set at -5.1.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -454.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1052.64.
Currently, EBITDA for the company is -18.86 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of -329.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
In conclusion, Cns Pharmaceuticals Inc (CNSP) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
